Patrick H. van Berkel

858 total citations
35 papers, 496 citations indexed

About

Patrick H. van Berkel is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Patrick H. van Berkel has authored 35 papers receiving a total of 496 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 12 papers in Molecular Biology and 10 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Patrick H. van Berkel's work include CAR-T cell therapy research (15 papers), HER2/EGFR in Cancer Research (11 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Patrick H. van Berkel is often cited by papers focused on CAR-T cell therapy research (15 papers), HER2/EGFR in Cancer Research (11 papers) and Synthesis and pharmacology of benzodiazepine derivatives (9 papers). Patrick H. van Berkel collaborates with scholars based in United Kingdom, Switzerland and United States. Patrick H. van Berkel's co-authors include Francesca Zammarchi, John A. Hartley, Simon Chivers, Philip W. Howard, David G. Williams, Simon Corbett, Arnaud Tiberghien, Carin E.G. Havenith, Peter Tyrer and Lauren Adams and has published in prestigious journals such as Blood, Cancer Research and Scientific Reports.

In The Last Decade

Patrick H. van Berkel

31 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Patrick H. van Berkel United Kingdom 9 393 181 113 112 96 35 496
Gregory E. Jones United States 8 463 1.2× 350 1.9× 36 0.3× 188 1.7× 64 0.7× 15 622
Leanne Lanieri United States 7 179 0.5× 137 0.8× 43 0.4× 86 0.8× 33 0.3× 17 286
Alan Wilhelm United States 9 273 0.7× 154 0.9× 29 0.3× 128 1.1× 47 0.5× 22 388
Josefa Chuh United States 7 263 0.7× 247 1.4× 21 0.2× 138 1.2× 54 0.6× 9 397
Nicole Adrian Germany 8 323 0.8× 111 0.6× 192 1.7× 85 0.8× 131 1.4× 10 428
Jenny Craigen United Kingdom 8 375 1.0× 232 1.3× 101 0.9× 202 1.8× 197 2.1× 11 660
Shui‐on Leung United States 10 168 0.4× 307 1.7× 124 1.1× 164 1.5× 131 1.4× 28 472
Kelly Foster United States 8 180 0.5× 38 0.2× 63 0.6× 285 2.5× 68 0.7× 10 444
Diane L. Rossi United States 9 291 0.7× 222 1.2× 39 0.3× 139 1.2× 175 1.8× 16 462
Kelly Davis Orcutt United States 13 155 0.4× 334 1.8× 32 0.3× 201 1.8× 57 0.6× 25 510

Countries citing papers authored by Patrick H. van Berkel

Since Specialization
Citations

This map shows the geographic impact of Patrick H. van Berkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick H. van Berkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick H. van Berkel more than expected).

Fields of papers citing papers by Patrick H. van Berkel

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick H. van Berkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick H. van Berkel. The network helps show where Patrick H. van Berkel may publish in the future.

Co-authorship network of co-authors of Patrick H. van Berkel

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick H. van Berkel. A scholar is included among the top collaborators of Patrick H. van Berkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick H. van Berkel. Patrick H. van Berkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kendsersky, Nathan M., Nathaniel W. Mabe, Alvin Farrel, et al.. (2025). Lineage dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and -independent immunotherapeutic targets. Neuro-Oncology. 27(5). 1372–1384. 1 indexed citations
2.
Spriano, Filippo, Chiara Tarantelli, Eugenio Gaudio, et al.. (2024). Targeting CD25 + lymphoma cells with the antibody–drug conjugate camidanlumab tesirine as a single agent or in combination with targeted agents. British Journal of Haematology. 205(5). 1873–1882. 2 indexed citations
3.
Brown, Nicholas F., Elizabeth Murray, Philip W. Howard, et al.. (2024). Integrin-αvβ6 targeted peptide-toxin therapy in a novel αvβ6-expressing immunocompetent model of pancreatic cancer. Pancreatology. 24(3). 445–455. 5 indexed citations
4.
Zammarchi, Francesca, Karin Havenith, Narinder Janghra, et al.. (2024). ADCT-602, a Novel PBD Dimer–containing Antibody–Drug Conjugate for Treating CD22-positive Hematologic Malignancies. Molecular Cancer Therapeutics. 23(4). 520–531. 6 indexed citations
5.
Yeung, Jenny, Aiyin Liao, Winston Vetharoy, et al.. (2024). Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Molecular Therapy. 32(6). 1672–1686. 6 indexed citations
6.
Horsley, Elizabeth, et al.. (2024). Abstract 3122: Preclinical development of a novel camptothecin-based antibody-drug conjugate targeting solid tumors expressing Claudin-6. Cancer Research. 84(6_Supplement). 3122–3122. 2 indexed citations
7.
Zammarchi, Francesca, Karin Havenith, Veronica Gil, et al.. (2023). Abstract 2638: Preclinical development of ADCT-212, a PSMA-targeted antibody-drug conjugate employing the pyrrolobenzodiazepine dimer SG2000 for PSMA-expressing cancers. Cancer Research. 83(7_Supplement). 2638–2638. 2 indexed citations
8.
Corbett, Simon, Shiran Huang, Francesca Zammarchi, et al.. (2020). The Role of Specific ATP-Binding Cassette Transporters in the Acquired Resistance to Pyrrolobenzodiazepine Dimer–Containing Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 19(9). 1856–1865. 14 indexed citations
9.
Moore, Kate M., Ami V. Desai, Beatriz de Luxán‐Delgado, et al.. (2020). Integrin αvβ6-specific therapy for pancreatic cancer developed from foot-and-mouth-disease virus. Theranostics. 10(7). 2930–2942. 37 indexed citations
10.
11.
12.
Corbett, Simon, Francesca Zammarchi, Philip W. Howard, Patrick H. van Berkel, & John A. Hartley. (2019). Abstract 4750: The role of drug transporters in the acquired resistance to PBD dimer-containing antibody drug conjugates. Cancer Research. 79(13_Supplement). 4750–4750. 1 indexed citations
13.
Staudacher, Alexander H., Yanrui Li, Vasilios Liapis, et al.. (2018). APOMAB Antibody–Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo. Molecular Cancer Therapeutics. 18(2). 335–345. 15 indexed citations
14.
Hartley, John A., Michael Flynn, John P. Bingham, et al.. (2018). Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Scientific Reports. 8(1). 10479–10479. 85 indexed citations
15.
16.
Zammarchi, Francesca, Narinder Janghra, Simon Corbett, et al.. (2017). Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors. Cancer Research. 77(13_Supplement). 52–52. 4 indexed citations
17.
Flynn, Michael, Francesca Zammarchi, Peter Tyrer, et al.. (2016). ADCT-301, a Pyrrolobenzodiazepine (PBD) Dimer–Containing Antibody–Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Molecular Cancer Therapeutics. 15(11). 2709–2721. 85 indexed citations
18.
Zammarchi, Francesca, Simon Chivers, David G. Williams, et al.. (2016). ADCT-502, a novel pyrrolobenzodiazepine (PBD)-based antibody–drug conjugate (ADC) targeting low HER2-expressing solid cancers. European Journal of Cancer. 69. S28–S28. 14 indexed citations
19.
Flynn, Michael, Patrick H. van Berkel, Francesca Zammarchi, et al.. (2015). Mechanistic and Pharmacodynamic Studies of Adct-301, a Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies. Blood. 126(23). 1559–1559. 6 indexed citations
20.
Zammarchi, Francesca, David G. Williams, Lauren Adams, et al.. (2015). Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies. Blood. 126(23). 1564–1564. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gregory E. Jones Breakdown of academic impact, for papers by Leanne Lanieri Breakdown of academic impact, for papers by Alan Wilhelm Breakdown of academic impact, for papers by Josefa Chuh Breakdown of academic impact, for papers by Nicole Adrian Breakdown of academic impact, for papers by Jenny Craigen Breakdown of academic impact, for papers by Shui‐on Leung Breakdown of academic impact, for papers by Kelly Foster Breakdown of academic impact, for papers by Diane L. Rossi Breakdown of academic impact, for papers by Kelly Davis Orcutt
Rankless by CCL
2026